Figure 2.
Figure 2. Western blot titrations demonstrating the decrease in percentage of p-Crkl at increasing concentrations of imatinib in 2 patients with varying IC50imatinib. The top blot represents phosphorylated Crkl; the bottom blot, the nonphosphorylated Crkl. The graph demonstrates the variation in IC50imatinib in 15 patients enrolled to the TIDEL study.

Western blot titrations demonstrating the decrease in percentage of p-Crkl at increasing concentrations of imatinib in 2 patients with varying IC50imatinib. The top blot represents phosphorylated Crkl; the bottom blot, the nonphosphorylated Crkl. The graph demonstrates the variation in IC50imatinib in 15 patients enrolled to the TIDEL study.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal